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Summary
Background: Mesothelioma invades the tracts made by chest instrumentation.
Prophylactic radiotherapy is effective at preventing malignant seeding at these
sites.
Methods: We assessed the use and effectiveness of radiotherapy at our centre in 39
of the 40 patients identified with mesothelioma between January 2000 andee front matter & 2005
med.2005.09.034
ng author. Tel.: +44 186
ess: sophie@west66.freSeptember 2003.
Results: Thirty-seven (95%) patients received radiotherapy to their chest instru-
mentation site between 6 and 42 days (median 26 days) following the diagnosis of
mesothelioma. The radiotherapy field size varied, from 4 cm square to 14 10.5 cm.
The radiotherapy was given as 21Gy in 3 fractions over 1 week. In 3 patients (8%),
there was already tumour invasion of the skin at the time of radiotherapy. In 2 other
patients (5%), there was tumour recurrence following radiotherapy; in both this was
at the edge of the previous radiotherapy fields. Further treatment was administered
to an adjacent field in both. One patient with an indwelling pleural catheter
developed tumour growth at the catheter insertion site. This was treated
successfully with radiotherapy, with no catheter damage.
Conclusions: Prompt radiotherapy referral and radiotherapy field selection is
important to maximise the effect of radiotherapy given to prevent chest wall
tumour growth. There was no tumour growth in areas that were treated with
radiotherapy. Further chest interventions outside the radiotherapy field should be
followed with further radiotherapy.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Table 1 Table showing details of radiotherapy to tract sites in mesothelioma.
Marking of track site at time
of chest instrumentation
Ideally with India ink
Timing of radiotherapy Ideally 2 weeks following chest instrumentation
Clinical target volume (CTV) Needle or biopsy track, from skin to pleura, usually taking angle of instrument
insertion into account
Field size Clinical target volume (as above), with an additional margin of 2–2.5 cm for a
needle or 3–4 cm for a chest drain or thoracoscopy ¼ planning target volume
(PTV)
Beam Ideally electrons (10MeV) or 6MV photons with 1 cm chest wall bolus or 200 kV
photons without chest wall bolus, if electrons unavailable, or do not cover target
volume adequately
Dose 21Gy in 3 fractions in 1 week as an applied dose using a direct field
S.D. West et al.1038Introduction
Mesothelioma is a common malignant pleural
tumour, with an incidence predicted to rise until
2015–2020.1 Its growth pattern is usually by local
invasion, with metastases being a late phenomen-
on. It therefore invades the tracks made by chest
instrumentation, including pleural aspiration,
biopsy, chest drain and thoracoscopy. Prophylactic
radiotherapy has been found to be effective at
preventing malignant seeding at these sites in two
studies, one a randomised controlled trial, where a
40% control group tumour rate was reduced to zero
in the radiotherapy group.2,3 A delay in radio-
therapy of more than 2 months was found to be
associated with increased chest wall recurrence in
a non-randomised study.4 On the basis of this data,
management guidelines recommend prophylactic
radiotherapy within 4 weeks following any invasive
procedures.5 Although this treatment is clearly
successful in clinical trials, it is important to know
how trial results compare to clinical practice.
There has been no previous description of needle
tract metastases, their location and their relation
to the previous radiotherapy field. Therefore, we
report a review of a cohort of patients with
mesothelioma, to assess the efficacy of prophylac-
tic chest wall radiotherapy in a ‘‘real world’’
setting.Methods
We performed a retrospective review of the notes
of a cohort of patients with histopathologically
confirmed malignant pleural mesothelioma, receiv-
ing radiotherapy for prophylaxis against tumourinvasion into pleural instrumentation sites. All
patients presenting to the Oxford pleural clinic
with malignant mesothelioma between January
2000 and September 2003 were included in the
study. Follow-up was until death or to at least 6
months after radiotherapy, to confirm an appro-
priate clinical course. The prophylactic radiother-
apy was given with direct fields to an applied dose
of 21Gy in 3 fractions over 1 week as an out-patient
in all patients (see Table 1).2 Radiotherapy was
performed with electrons (10MeV). If electrons
were not available, 6MV photons with a 1 cm chest
wall bolus were used, or alternatively 200 kV
photons without a chest wall bolus. Radiotherapy
field sizes used were based on the current radio-
therapy guidelines at our centre, which suggest
allowing a 2–2.5 cm margin for a needle biopsy and
a 3–4 cm margin for a chest drain, aiming to
encompass any track made from the skin to the
pleura. The distance from the skin to the pleura is
obtained from the computerised tomography (CT)
scan (Fig. 1).Results
Forty patients who fulfilled the entry criteria with
mesothelioma were identified (see flow chart). The
clinical notes were missing for one patient,
generating available data for 39 (98% of subjects).
The histological diagnosis of mesothelioma was
made following thoracoscopy in 24 patients (62%);
in others it was made from pleural fluid, tumour or
lymph node examination. Epithelioid mesothelioma
accounted for 44%, sarcomatoid 13%, biphasic 5%
and the remaining 38% were mesothelioma of
unspecified type.
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40 patients with mesothelioma identified, January 2000-September 2003 
39 patient notes found Figure 1 Photograph of patient with mesothelioma with2 died rapidly after diagnosis, before radiotherapy 
   6 had indwelling pleural catheters, which were not irradiated 
37 patients received radiotherapy to pleural intervention sites 
Of these: 3 had tumour invasion at time of radiotherapy 
2 went on to develop tumour at the edge of the radiotherapy fields tumour from a tract site at the edge of his radiotherapy
field. When the patient lifts his arm to simulate the
position of his radiotherapy treatment, the relapsed
nodule is at the edge of the previous radiotherapy field
(published with patient’s consent).Thirty-seven (95%) patients received radiother-
apy to their chest procedure site. This began a
median of 26 days (range 6–43 days) following
referral after the histological diagnosis of mesothe-
lioma. The other 2 patients (5%) from the cohort
died rapidly after their diagnosis and did not
therefore receive radiotherapy. Radiotherapy field
sizes varied in size from 4 cm2 to 14 10.5 cm,
depending on whether one or multiple biopsy sites
were being irradiated, and whether a chest drain
had been inserted. The radiotherapy was well
tolerated, with few adverse effects, although most
patients described mild tiredness.
In 3 patients (8%) of the cohort, there was
already tumour invasion of the skin and chest wall
at the chest instrumentation site at the time of
radiotherapy (20, 27 and 38 days after diagnosis).
Two other patients (5%) developed chest wall
tumour following radiotherapy. One of these had
been treated with a large initial radiotherapy field
(10 7.5 cm) to encompass chest procedure sites,
and had further radiotherapy to a different field 3
months later, following further pleural aspirations.
However, he developed tumour presumed to be at
an unmarked aspiration site at the edge of one of
the previous fields 12 months after his initial
radiotherapy. The other patient had been treated
initially with 2 adjacent fields (10 5 cm and
4 cm2), but relapsed after 6 months with a nodule
at the edge of one of the previously treated fields.
Both patients received further radiotherapy to a
field adjacent to, but not overlapping, the previous
field, at a dose of either 21 or 24Gy in 3 fractions
over 1 week. In all the other patients, there was no
tumour growth within areas that had been treated
with prophylactic radiotherapy. A Kaplan–Meier
survival analysis was performed to define radio-
therapy field relapse rate over time: at 6 months,
the proportion surviving without radiotherapy field
relapse was 0.96; at 12 months, the proportion
surviving without radiotherapy field relapse was
0.96; at 24 months, the proportion surviving with-out radiotherapy field relapse was 0.9 and at 48
months, the proportion surviving without radio-
therapy field relapse was 0.9.
Six patients (15%) of the cohort had indwelling
catheters (Denver Pleurx, CLS Medical) inserted for
persistent pleural fluid and trapped lung. These
patients did not receive prophylactic radiotherapy
whilst the catheter was indwelling. One patient
developed painful tumour growth from the chest
insertion site into the pleural cavity to the catheter
exit site, whilst the catheter was in situ, 6 months
after its insertion. He received radiotherapy (30Gy
in 6 fractions) to a field encompassing the drain
insertion point, whilst the catheter remained in
situ, with no adverse effect on the catheter. There
was some shrinkage of the tumour following radio-
therapy. However 7 months later, further sub-
cutaneous nodules developed on top of the tumour
which had previously been irradiated. No further
radiotherapy was given to this site.
Follow up of patients with mesothelioma follow-
ing radiotherapy was at regular intervals by the
physicians in the specialist pleural disease clinic.
They were able to correlate symptoms of chest wall
discomfort with the clinical disease progression and
observe sites of chest wall irradiation for possible
tumour growth. Patient survival was a median of 11
months following needle track radiotherapy (range
1 month–still alive at 57 months).Discussion
Our cohort compares in size favourably to those
used in previous published works (Boutin: 40
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S.D. West et al.1040patients,2 Low: 20 patients over 4 years,3 de Graaf-
Strukowska: 189 patients over 17 years6). As 8% of
our patients had developed tumour invasion by the
time of radiotherapy, the need for prompt radio-
therapy referral and early treatment following
chest instrumentation in all patients is highlighted.
The aim of our department is to commence
irradiation within 2 weeks of chest instrumenta-
tion, but current practice is somewhat slower than
this. There were two episodes of track site invasion
following radiotherapy: one at a presumed unrec-
ognised procedure site at the edge of the initial
radiotherapy treatment field and one at the edge of
the radiotherapy field. This was much lower than
the control frequency of this problem in clinical
trials.2 The edge of a radiotherapy field receives a
lower radiation dose than the centre of the field
and had the procedure site been marked, the
original radiotherapy field could have been in-
creased in order to encompass it. This emphasises
that field selection is crucial to encompass all
pleural procedure sites and a minimum field size of
4 cm2 for simple aspiration/biopsy and 6 cm2 mini-
mum for chest drain/thoracoscopy is needed to
maximise patient benefit from radiotherapy. Larger
field sizes are used if there are adjacent biopsy or
aspiration sites, which all need encompassing
within the treatment field. It is now our practice
to mark all biopsy and aspiration sites in potential
mesothelioma cases with Indian ink, so that radio-
therapy fields can be adjusted to reliably incorpo-
rate all these sites. Any further chest interventions
outside the radiotherapy field should be followed
with further radiotherapy.
The indwelling pleural catheters used for persis-
tent pleural fluid and trapped lung are tunnelled
semi-permanent catheters which patients them-
selves can access and drain fluid from as required.7
There is a permanent tract created by these
catheters. The likelihood of mesothelioma seeding
down these tracts whilst the catheter is in situ is
unknown. The use of radiotherapy for prophylaxis
against tract tumours whilst the catheter is in situ
is also untested, as are the effects of radiotherapy
on indwelling catheters. The patient in our cohort
who developed tumour around the catheter inser-
tion point had persistent pleural fluid leakage
problems around the drain exit point since it was
inserted. It was postulated that the fluid leak mayhave contributed to the tumour growth, by allowing
seeding of mesothelioma cells along the track. He
responded well to radiotherapy, with no adverse
effect on the catheter, despite high radiotherapy
doses. The nodules which developed over the
tumour 7 months after the radiotherapy were
most likely due to the progression of his underlying
disease. Similar tumour growth due to seeding
from a fluid leak along a catheter track has
been previously described in mesothelioma,
in a case where the chest drain was used for
intrapleural chemotherapy.8 It is not our
routine practice to irradiate indwelling pleural
catheters.
In conclusion, radiotherapy is well-tolerated and
effective at preventing mesothelioma seeding at
chest instrumentation sites in subjects who do not
have clinical evidence of track tumour growth
already present at the time of treatment.References
1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing
increase in mesothelioma mortality in Britain. Lancet
1995;345:535–9.
2. Boutin C, Rey F, Villiat JR. Prevention of malignant seeding
after invasive diagnostic procedures in patients with pleural
mesothelioma. A randomized trial of local radiotherapy.
Chest 1995;108:754–8.
3. Low EM, Khoury GG, Matthews AW, Neville E. Prevention of
tumour seeding following thoracoscopy in mesothelioma by
prophylactic radiotherapy. Clin Oncol (R Coll Radiol) 1995;
7(5):317–8.
4. Boutin C, Irrisson M, Rathelot P, Petite JM. Parietal extension
of diffuse malignant pleural mesothelioma after biopsy.
Prevention by local radiotherapy. Presse Med 1983;12(29):
1823.
5. BTS Statement on malignant mesothelioma in the United
Kingdom. Thorax 2001;56:250–65.
6. De Graaf-Strukowska LA, van der Zee J, van Putten W, Senan
S. Factors influencing the outcome of radiotherapy in
malignant mesothelioma of the pleura—a single institution
experience with 189 patients. Int J Radiat Oncol Biol Phys
1999;43(3):511–6.
7. Robinson RD, Fullerton DA, Albert JD, et al. Use of Pleural
Tenckhoff Catheter to palliate malignant pleural effusion.
Ann Thorac Surg 1994;57:286–8.
8. Sartori S, Nielsen I, Trevisani L, et al. Subcutaneous seeding
after ultrasound- guided placement of intrapleural catheter.
An unusual complication of the intracavitary palliative
treatment of pleural mesothelioma. Support Care Cancer
1999;7(5):362–4.
